Seeking AlphaMon, 08 Jun 2026 23:18:31 GMTKeros Therapeutics, Inc. (KROS) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 TranscriptKROS-2.98%
Zacks Investment ResearchFri, 22 May 2026 16:11:14 GMTShould You Buy KROS After Q1 Miss and Takeda Deal Reset?KROS-2.98%
Zacks Investment ResearchFri, 22 May 2026 16:11:09 GMTKROS Turns to Next Wave of TGF-Beta Muscle TherapiesKROS-2.98%
Zacks Investment ResearchFri, 22 May 2026 16:06:06 GMTKROS Stock Guide to Rinvatercept in DMD and ALS for 2026KROS-2.98%
Zacks Investment ResearchFri, 15 May 2026 17:11:30 GMTKeros Q1 Loss Wider Than Expected, Revenues Plunge Year Over YearKROS-2.98%
Zacks Investment ResearchThu, 14 May 2026 14:10:26 GMTKeros Therapeutics, Inc. (KROS) Reports Q1 Loss, Misses Revenue EstimatesKROS-2.98%
Zacks Investment ResearchMon, 20 Apr 2026 16:46:29 GMTKROS 2026 Watchlist: 3 Catalysts That Could Reset SentimentKROS-2.98%
Zacks Investment ResearchMon, 20 Apr 2026 16:41:33 GMTKROS Stock: Does the Takeda Deal Lower Dilution Risk in 2026?KROS-2.98%
Zacks Investment ResearchMon, 20 Apr 2026 16:30:29 GMTKROS Rinvatercept: What to Know Before DMD Phase II StartsKROS-2.98%
Zacks Investment ResearchFri, 03 Apr 2026 16:31:16 GMTWhy Is Keros Therapeutics (KROS) Up 2.5% Since Last Earnings Report?KROS-2.98%
